CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma

Liver International

Volumn 34, Issue 6, 2014, Pages

  Zhao, Rui ^a   Wang, Nisha ^a   Huang, Haili ^b   Ma, Wenli ^a   Yan, Qitao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Aberrant methylation; CHD5; Hepatocellular carcinoma; Tumour suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CHD5 PROTEIN, HUMAN; DNA HELICASE; MESSENGER RNA; NERVE PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CARCINOGENICITY; CELL PROLIFERATION; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5 GENE; COLONY FORMATION; CONTROLLED STUDY; DNA BINDING; DNA METHYLATION; DNA MODIFICATION; FETUS; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; TUMOR GENE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ADULT; AGED; ANIMAL; CASE CONTROL STUDY; CELL AGING; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; TIME; TUMOR VOLUME; YOUNG ADULT;

ADULT; AGED; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL AGING; CELL PROLIFERATION; DNA HELICASES; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE, NUDE; MIDDLE AGED; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84902540348     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12503     Document Type: Article

References (49)

1. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003; 22: 1002-11.
2. Eisen JA, Sweder KS, Hanawalt PC. Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucleic Acids Res 1995; 23: 2715-23.
3. Flanagan JF, Mi LZ, Chruszcz M, et al. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 2005; 438: 1181-5.
4. Sims RJ, 3rd, Chen CF, Santos-Rosa H, et al. Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains. J Biol Chem 2005; 280: 41789-92.
5. Marfella CG, Imbalzano AN. The Chd family of chromatin remodelers. Mutat Res 2007; 618: 30-40.
6. De La Serna IL, Ohkawa Y, Imbalzano AN. Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 2006; 7: 461-73.
7. Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer 1977; 40: 2256-63.
8. White PS, Maris JM, Beltinger C, et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A 1995; 92: 5520-4.
9. White PS, Thompson PM, Gotoh T, et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005; 24: 2684-94.
10. Piaskowski S, Rieske P, Szybka M, et al. GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet 2005; 162: 63-7.
11. Poetsch M, Dittberner T, Woenckhaus C. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 2003; 13: 29-33.
12. Melendez B, Cuadros M, Robledo M, et al. Coincidental LOH regions in mouse and humans: evidence for novel tumor suppressor loci at 9q22-q34 in non-Hodgkin's lymphomas. Leuk Res 2003; 27: 627-33.
13. Mori N, Morosetti R, Mizoguchi H, Koeffler HP. Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. Br J Haematol 2003; 122: 226-30.
14. Mori N, Morosetti R, Spira S, et al. Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 1998; 92: 3405-9.
15. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995; 64: 207-10.
16. Moley JF, Brother MB, Fong CT, et al. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 1992; 52: 770-4.
17. Kleer CG, Bryant BR, Giordano TJ, Sobel M, Merino MJ. Genetic changes in chromosomes 1p and 17p in thyroid cancer progression. Endocr Pathol 2000; 11: 137-43.
18. Praml C, Finke LH, Herfarth C, et al. Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 1995; 11: 1357-62.
19. Cheung TH, Lo KW, Yim SF, et al. Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer. Gynecol Oncol 2005; 96: 510-5.
20. Bieche I, Champeme MH, Matifas F, et al. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 1993; 53: 1990-4.
21. Bello MJ, Leone PE, Nebreda P, et al. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 1995; 83: 160-4.
22. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007; 104: 20007-12.
23. Law ME, Templeton KL, Kitange G, et al. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 2005; 160: 1-14.
24. Bagchi A, Papazoglu C, Wu Y, et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007; 128: 459-75.
25. Koyama H, Zhuang T, Light JE, et al. Mechanisms of CHD5 Inactivation in neuroblastomas. Clin Cancer Res 2012; 18: 1588-97.
26. Mokarram P, Kumar K, Brim H, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS ONE 2009; 4: e7012.
27. Mulero-Navarro S, Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 2008; 3: 210-5.
28. Wang X, Lau KK, So LK, Lam YW. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci 2009; 16: 95.
29. Zhao R, Yan Q, Lv J, et al. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 2012; 76: 324-31.
30. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-7.
31. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-20.
32. Gorringe KL, Choong DY, Williams LH, et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 2008; 10: 1253-8.
33. Jones S, Wang TL, Shih IEM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-31.
34. Lang J, Tobias ES, Mackie R. Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br J Dermatol 2011; 164: 1010-6.
35. Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43: 828-9.
36. Okawa ER, Gotoh T, Manne J, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008; 27: 803-10.
37. Robbins CM, Tembe WA, Baker A, et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011; 21: 47-55.
38. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-74.
39. Mallette FA, Richard S. JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Rep 2013; 2: 1233-43.
40. Song MA, Tiirikainen M, Kwee S, et al. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS ONE 2013; 8: e55761.
41. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003; 163: 1101-7.
42. Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-22.
43. Lee S, Lee HJ, Kim JH, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003; 163: 1371-8.
44. Bock C, Reither S, Mikeska T, et al. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005; 21: 4067-8.
45. Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008; 100: 940-9.
46. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92: 9363-7.
47. Cai C, Ashktorab H, Pang X, et al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS ONE 2012; 7: e29750.
48. Wu X, Zhu Z, Li W, et al. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res 2012; 14: R73.
49. Paul S, Kuo A, Schalch T, et al. Chd5 requires PHD-mediated histone 3 binding for tumor suppression. Cell Rep 2013; 3: 92-102.